Tracking Baker Brothers Portfolio – Q2 2020 Update

• Baker Brothers’ 13F portfolio value increased from $16.24B to $22.67B this quarter. 
• Stakes in InVitae and MyoKardia were increased substantially while reducing Neurocrine Biosciences and Principia Biopharma. 
• The top three positions are Seattle Genetics, Incyte Corporation, and BeiGene Ltd. and they add up to almost ~61% of the portfolio. 

This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 08/14/2020.

 

This quarter, Baker Brothers’ 13F portfolio value increased ~40% from ~$16.24B to $22.67B. The top three holdings are at ~60% while the top five holdings are at ~73% of the 13F assets: Seattle Genetics (SGEN), Incyte Corporation (INCY), BeiGene (BGNE), Acadia Pharma (ACAD), and Alexion Pharmaceuticals (ALXN).

 

The spreadsheet below highlights changes to Baker Brothers’ 13F holdings in Q2 2020. For a look at how the portfolio has progressed, please see our previous update:

 

 

 

To learn more about how to profit from a strategy of following the best hedge fund picks, check out our book Profiting from Hedge Funds: Winning Strategies for the Little Guy .